5.02

1.57% -0.08

Evotec SE ADR (EVO)

Overview News Price History Why EVO Down? Discussions Forecast Stock Split Dividend History

Evotec SE ADR stock is currently priced at $5.02, with a 24-hour trading volume of 869.09K. It has seen a -1.57% decreased in the last 24 hours and a -32.62% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $5.03 pivot point. If it approaches the $4.94 support level, significant changes may occur.

Previous Close:

$5.10

Open:

$5.04

24h Volume:

869.09K

Market Cap:

$1.78B

Revenue:

$862.29M

Net Income/Loss:

$-103.88M

P/E Ratio:

-14.70

EPS:

-0.3415

Net Cash Flow:

$22.94M

1W Performance:

-29.00%

1M Performance:

-32.62%

6M Performance:

-43.72%

1Y Performance:

-44.41%

1D Range:

$4.99

$5.11

52W Range:

$4.8701

$13.49

Evotec SE ADR Stock (EVO) Company Profile

Name

Evotec SE ADR

Sector

Healthcare (1191)

Industry

Drug Manufacturers - Specialty & Generic (4)

Phone

49 40 560 81 0

Address

Essener Bogen 7, Hamburg

Employee

4,081

Twitter

Next Earnings Date

Latest SEC Filings

EVO's Discussions on Twitter

Evotec SE ADR Stock (EVO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-18-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jun-23-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-16-23	Downgrade	BofA Securities	Buy → Neutral
Jun-08-23	Upgrade	Citigroup	Neutral → Buy
Apr-04-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Dec-09-22	Initiated	H.C. Wainwright	Buy
Nov-16-22	Downgrade	Deutsche Bank	Buy → Hold
Aug-10-22	Downgrade	Morgan Stanley	Overweight → Underweight
Mar-02-22	Resumed	Cowen	Outperform
Jan-07-22	Resumed	Citigroup	Neutral

View All

Evotec SE ADR Stock (EVO) Latest News

Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

Why Resources Connection Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket

Benzinga

Cal-Maine Posts Downbeat Q2 Results, Joins Dyne Therapeutics, OPKO Health And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Benzinga

Evotec SE ADR Stock (EVO) Financials Data

Evotec SE ADR (EVO) Revenue 2024

EVO reported a revenue (TTM) of $862.29 million for the quarter ending December 31, 2023, a +13.86% rise year-over-year.

Evotec SE ADR (EVO) Net Income 2024

EVO net income (TTM) was -$103.88 million for the quarter ending December 31, 2023, a +46.88% increase year-over-year.

Evotec SE ADR (EVO) Cash Flow 2024

EVO recorded a free cash flow (TTM) of $22.94 million for the quarter ending December 31, 2022, a +488.59% increase year-over-year.

Evotec SE ADR (EVO) Earnings per Share 2024

EVO earnings per share (TTM) was -$0.2885 for the quarter ending December 31, 2023, a +48.99% growth year-over-year.

Evotec SE operates as a drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as neuronal diseases, diabetes and complications of diabetes, pain, inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases, and women's health. It has collaboration agreements with Bayer AG; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Celgene; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.